Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Allogene Therapeutics (ALLO) Return on Capital Employed: 2019-2025

Historic Return on Capital Employed for Allogene Therapeutics (ALLO) over the last 6 years, with Sep 2025 value amounting to -0.54%.

  • Allogene Therapeutics' Return on Capital Employed fell 3.00% to -0.54% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.54%, marking a year-over-year decrease of 3.00%. This contributed to the annual value of -0.49% for FY2024, which is 2.00% down from last year.
  • Latest data reveals that Allogene Therapeutics reported Return on Capital Employed of -0.54% as of Q3 2025, which was up 3.33% from -0.56% recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Return on Capital Employed registered a high of -0.18% during Q4 2021, and its lowest value of -0.56% during Q2 2025.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.51% (2024), whereas its average is -0.51%.
  • In the last 5 years, Allogene Therapeutics' Return on Capital Employed climbed by 13bps in 2021 and then declined by 26bps in 2023.
  • Allogene Therapeutics' Return on Capital Employed (Quarterly) stood at -0.18% in 2021, then dropped by 24bps to -0.42% in 2022, then declined by 9bps to -0.51% in 2023, then remained steady at -0.51% in 2024, then dropped by 3bps to -0.54% in 2025.
  • Its Return on Capital Employed stands at -0.54% for Q3 2025, versus -0.56% for Q2 2025 and -0.54% for Q1 2025.